British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

The Centers for Disease Control and Prevention (CDC) recommends that pregnant women receive an RSV vaccine during their third ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Blog - A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

The Royal Australian College of GPs (RACGP) has welcomed a new Victorian Government program to provide free respiratory syncytial virus (RSV) vaccines ...